Vireo Growth (K95) AI Stock Analysis
Vireo Growth
(Frankfurt:K95)
No summary available
Vireo Growth (K95) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 281.16M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -4.1
- Beta (1Y)
- -4.82
- Revenue Growth
- 291.66%
- EPS Growth
- 55.18%
- Country
- Germany
- Employees
- 490
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Pharmaceuticals
Vireo Growth Business Overview & Revenue Model
Company Description
Vireo Health International, Inc. is a holding company, which engages in the cultivation, production, and sale of medical cannabis. Its products include medical marijuana extracts in the form of oils, vaporizers, and capsules. The company was founded...
Vireo Growth Earnings Call Summary
The call presents a predominantly positive operational and financial trajectory: exceptionally large reported and pro forma revenue growth, a >$1B annualized run rate, improved adjusted EBITDA and near break‑even net loss, meaningful liquidity, and ambitious footprint expansion. Offsetting these positives are margin compression at the consolidated level driven by lower‑margin non‑cannabis additions and recently acquired businesses, plus execution and regulatory risk as multiple announced transactions await closing and integration.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company guided that its pro forma Q2 performance puts it on a greater-than-$1.0 billion annualized run rate (pro forma Q2 revenue $254.9M vs. GAAP Q2 revenue $209.3M, +335% YoY), and said it expects to operate roughly 270 dispensaries across 15 states (today ~170 dispensaries in 10 states) upon closing announced deals; management reiterated objectives to generate non‑volatile free cash flow, build $100M+ revenue businesses in each core state, and deliver consistent same‑store sales growth (pro forma cannabis same‑store/retail growth ~7% in the quarter, with a longer‑term target of low single‑digit growth above inflation). Key near‑term financials discussed as context include Q2 cannabis revenue $175.8M (+265% YoY) and non‑cannabis $33.5M, adjusted gross margin 47% excluding non‑cash inventory adjustments (cannabis adj. gross margin 53%, non‑cannabis 18%), adjusted EBITDA ~$41.5M (19.8% of sales; adjusted EBITDA margin down 790 bps YoY to reflect lower‑margin acquisitions and non‑cannabis at 6.3%), Q2 net loss $0.1M (vs. $14.9M loss YoY), cash $122.7M (+$1M marketable securities), and a $65M ABL (expandable to $85M / $105M via accordion) priced at Term SOFR+1.75–2% (currently ~5.37–5.62%); management expects 2027 to provide a clearer financial picture of the strategy.
Vireo Growth Risk Analysis
Vireo Growth disclosed 77 risk factors in its most recent earnings report. Vireo Growth reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksVireo Growth Peers Comparison
Overall Rating
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:K95 | Vireo Growth Inc | 6.96 | -8.64 | -55.38% | |
| TSE:NU.H | NeutriSci International | 0.01 | 0.00 | 0.00% | |
| TSE:ZYUS | Zyus Life Sciences Corporation | 0.37 | -0.33 | -47.14% | |
| TSE:HERB | Luff Enterprises Ltd. | 0.03 | -0.06 | -66.67% | |
| TSE:STRC.X | Hash Corporation | 0.01 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.